Nasal Spray News and Research

RSS

Egalet declares pricing of underwritten public offering of common stock

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $11.25 per share.

28 Jul 2015

Educational messages about naloxone's lifesaving benefits can bolster support for its use

While most Americans do not support policies designed to increase distribution of naloxone - a medication that reverses the effects of a drug overdose - certain types of educational messages about its lifesaving benefits may bolster support for its use, new Johns Hopkins Bloomberg School of Public Health research suggests.

2 Jul 2015

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015.

7 May 2015

UNC researchers use exosomes to deliver potent Parkinson's treatment directly to the brain

Researchers at the University of North Carolina at Chapel Hill have used exosomes -- tiny bubbles of protein and fat produced naturally by cells -- to bypass the body's defenses and deliver a potent antioxidant directly to the brain to treat Parkinson's disease.

5 May 2015

New fluid gels delay release of drugs to benefit young children, others

SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect.

27 Apr 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Flu vaccine based upon four strains of inactivated influenza enhances flu protection

A flu vaccine given just under the surface of the skin that includes four strains of inactivated influenza could be more protective than a similar flu vaccine containing only three strains, Saint Louis University research found.

16 Mar 2015

Oxytocin nasal spray helps healthy men reduce consumption of fatty foods

A synthetic nasal formulation of the hormone oxytocin reduced caloric intake in healthy men, particularly consumption of fatty foods, after a single treatment, a new study finds. The results, to be presented Sunday at The Endocrine Society's 97th annual meeting in San Diego, confirm those of animal studies showing oxytocin reduces food intake.

6 Mar 2015

Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

After marijuana and alcohol, the most commonly abused drugs by those over the age of 14 are prescription and over-the-counter medications.

28 Feb 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

AHS provides updated assessment of treatments for acute migraine

The January issue of the American Headache Society journal Headache provides an updated assessment of the best treatments to use when a migraine attack occurs. The assessment will form the basis of new AHS treatment guidelines.

21 Jan 2015

Man-made insulin nasal spray may improve memory in adults with Alzheimer's-related dementia

A man-made form of insulin delivered by nasal spray may improve working memory and other mental capabilities in adults with mild cognitive impairment and Alzheimer's disease dementia, according to a pilot study led by researchers at Wake Forest Baptist Medical Center.

9 Jan 2015

Everyday actions could help prevent spread of flu among college students

As local college students return to Philadelphia from their long winter breaks over the next several days, it is likely that they'll be bringing who-knows-what germs with them from home, said Stacey A. Gorski, PhD, a biology professor who specializes in immunology at University of the Sciences in Philadelphia.

7 Jan 2015

Infectious disease specialist underscores the importance of flu vaccines

Flu season is in full swing, but it's not too late to get a flu vaccine. In fact, it's never been easier and more convenient.

23 Dec 2014

Immunizing school-aged children from flu can protect others as well

Mathematical models predicted it, and now a University of Florida study confirms it: Immunizing school-aged children from flu can protect other segments of the population, as well.

10 Dec 2014

Corrective information can successfully reduce false beliefs about flu vaccines

With health systems in the U.S., U.K., and around the world trying to increase vaccination levels, it is critical to understand how to address vaccine hesitancy and counter myths about vaccine safety. A new article in the journal "Vaccine" concludes, however, that correcting myths about vaccines may not be the most effective approach to promoting immunization among vaccine skeptics.

8 Dec 2014

Oxytocin hormone inhibits fear center in brain, shows study

Frightening experiences do not quickly fade from memory. A team of researchers under the guidance of the University of Bonn Hospital has now been able to demonstrate in a study that the bonding hormone oxytocin inhibits the fear center in the brain and allows fear stimuli to subside more easily.

14 Nov 2014

LSTM receives research grants to develop Experimental Human Pneumococcal Carriage model

Respiratory specialists at Liverpool School Tropical Medicine (LSTM) have been awarded two substantial research grants to further develop and utilise their Experimental Human Pneumococcal Carriage (EHPC) model.

10 Nov 2014

LSTM awarded research grants to develop Experimental Human Pneumococcal Carriage model

Respiratory specialists at Liverpool School Tropical Medicine have been awarded two substantial research grants to further develop and utilise their Experimental Human Pneumococcal Carriage (EHPC) model.

7 Nov 2014

Nasal vaccine shows promise against Ebola virus

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.

4 Nov 2014